$406 Million is the total value of Octagon Capital Advisors LP's 30 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 29.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMAB | Sell | I MABsponsored ads | $55,416,000 | -30.0% | 764,461 | -18.9% | 13.64% | -16.8% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $52,601,000 | -33.7% | 1,595,911 | +27.0% | 12.95% | -21.2% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $41,108,000 | +119.0% | 761,398 | +35.6% | 10.12% | +160.3% |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $33,830,000 | +62.1% | 970,164 | +27.6% | 8.33% | +92.7% |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $26,688,000 | +14.9% | 569,414 | +49.5% | 6.57% | +36.6% |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $22,419,000 | +12.0% | 831,267 | 0.0% | 5.52% | +33.1% | |
| GOSS | Buy | GOSSAMER BIO INC | $19,020,000 | +65.8% | 1,513,138 | +7.1% | 4.68% | +97.0% |
| CRIS | Sell | CURIS INC | $17,968,000 | -37.9% | 2,294,721 | -35.9% | 4.42% | -26.1% |
| IPSC | Buy | CENTURY THERAPEUTICS INC | $15,162,000 | +28.1% | 602,623 | +49.3% | 3.73% | +52.2% |
| ARVN | Sell | ARVINAS INC | $13,847,000 | +0.7% | 168,500 | -5.6% | 3.41% | +19.7% |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $12,078,000 | -19.5% | 696,126 | -38.5% | 2.97% | -4.3% |
| RNA | AVIDITY BIOSCIENCES INC | $11,001,000 | -0.3% | 446,641 | 0.0% | 2.71% | +18.5% | |
| New | CYTEK BIOSCIENCES INC | $10,705,000 | – | 500,000 | +100.0% | 2.64% | – | |
| DYN | DYNE THERAPEUTICS INC | $9,478,000 | -22.8% | 583,649 | 0.0% | 2.33% | -8.2% | |
| CNTB | Sell | CONNECT BIOPHARMA HLDGS LTDads | $7,795,000 | +6.9% | 326,143 | -12.7% | 1.92% | +27.0% |
| STOK | STOKE THERAPEUTICS INC | $7,551,000 | -24.4% | 296,822 | 0.0% | 1.86% | -10.1% | |
| New | OMEGA THERAPEUTICS INC | $6,980,000 | – | 370,279 | +100.0% | 1.72% | – | |
| CRDF | CARDIFF ONCOLOGY INC | $6,545,000 | +0.2% | 982,753 | 0.0% | 1.61% | +19.0% | |
| RXDX | PROMETHEUS BIOSCIENCES INC | $4,742,000 | -3.5% | 200,000 | 0.0% | 1.17% | +14.8% | |
| AMAM | Sell | AMBRX BIOPHARMA INCsponsored ads | $4,725,000 | -46.4% | 350,000 | -22.2% | 1.16% | -36.3% |
| ISEE | Sell | IVERIC BIO INC | $4,499,000 | +4.8% | 277,057 | -59.3% | 1.11% | +24.6% |
| NGM | NGM BIOPHARMACEUTICALS INC | $4,204,000 | +6.6% | 200,000 | 0.0% | 1.04% | +26.7% | |
| HLXA | HELIX ACQUISITION CORP | $3,948,000 | -4.5% | 400,000 | 0.0% | 0.97% | +13.6% | |
| IKNA | Sell | IKENA ONCOLOGY INC | $3,471,000 | -38.2% | 275,000 | -31.2% | 0.86% | -26.5% |
| GLUE | Sell | MONTE ROSA THERAPEUTICS INC | $3,342,000 | -38.2% | 150,000 | -37.0% | 0.82% | -26.5% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $2,984,000 | -65.1% | 100,141 | -59.9% | 0.74% | -58.5% |
| JYAC | JIYA ACQUISITION CORP | $2,934,000 | -1.6% | 300,000 | 0.0% | 0.72% | +16.8% | |
| EWTX | Sell | EDGEWISE THERAPEUTICS INC | $830,000 | -68.9% | 50,000 | -60.0% | 0.20% | -63.0% |
| DSGN | Sell | DESIGN THERAPEUTICS INC | $219,000 | -95.6% | 14,926 | -94.0% | 0.05% | -94.8% |
| New | TENAX THERAPEUTICS INC | $54,000 | – | 30,600 | +100.0% | 0.01% | – | |
| KRON | Exit | KRONOS BIO INC | $0 | – | -146,173 | -100.0% | -0.72% | – |
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -126,136 | -100.0% | -0.83% | – |
| MRUS | Exit | MERUS N V | $0 | – | -206,927 | -100.0% | -0.90% | – |
| KYMR | Exit | KYMERA THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -1.00% | – |
| TSHA | Exit | TAYSHA GENE THERAPIES INC | $0 | – | -320,440 | -100.0% | -1.41% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -112,363 | -100.0% | -2.92% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -109,335 | -100.0% | -4.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.